parallel randomized trial

S002899

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)S002899

Design

Randomized: 70
Start year: 2021
Treatment: 52.14 weeks, follow-up 52.14 weeks
Countries: China (1 sites)
Sponsor: (non industry)
Eligibility: type 2 diabetes; age 20 to 80; BMI 24 or more; GLP-1 RA naive

Conduct and analysis

Blinding: not reported
Sequence generation: other adequate
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: completers
Missing data: completers only

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Standard care or no added treatment Control group (metformin)	metformin; lifestyle: standard	35	35
A2	dulaglutide or semaglutide Test group (metformin plus dulaglutide or semaglutide)	metformin; lifestyle: standard	35	32

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Standard care or no added treatment A1	Test group (metformin plus dulaglutide or semaglutide) A2
age	mean (years)	54.57	55.81
age	sd (years)	10.05	10.91
bmi	mean (kg/m2)	27.74	27.77
bmi	sd (kg/m2)	2.33	3.25
diabetes duration	mean (years)	7.87	6.68
diabetes duration	sd (years)	3.86	3.60
female	n	16	14
female	percent	45.71	43.75
hba1c	mean (percent)	8.98	8.58
hba1c	sd (percent)	1.48	1.68

Results

4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Level 2 or 3 hypoglycemia (participants) (4 lines; O04)

Arm	Statistic	Detail
A1	events	not stated; other; R0003761:Results
A1	events	not stated; other; R0003761:Results
A2	events	not stated; other; R0003761:Results
A2	events	not stated; other; R0003761:Results